Special Issue

Advanced Research on the Role of Biogenic Amines in Physiological and Pathological Conditions

Message from the Guest Editors

Biogenic amines are a class of neurotransmitters derived from amino acids that are essential for maintaining homeostasis in both the central nervous system (CNS) and the peripheral nervous system (PNS). In the CNS, these neurotransmitters are pivotal for numerous physiological functions, including cognitive processes like learning and memory, regulating emotional responses, and facilitating signal transmission across synapses, impacting overall brain function. Recent research has highlighted the involvement of biogenic amines in various pathological conditions. Imbalances in biogenic amines are linked to mental health disorders such as depression, anxiety, schizophrenia, and neurodegenerative diseases such as Parkinson's and Alzheimer's disorders. Moreover, emerging studies suggest a role for biogenic amines in the progression of malignant tumors, such as gliomas. This Special Issue invites original research and reviews on all aspects of biogenic amines in the CNS. We seek contributions that enhance our understanding of their biological effects and explore their potential therapeutic applications.

Guest Editors

Dr. Pellegrino Lippiello

Dr. Luisa Speranza

Dr. Maria Grazia Ferraro

Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/209151

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).